Literature DB >> 31997057

Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs.

Jonathan Picard1, Brendan Jacka1, Stine Høj1, Émélie Laverdière2, Joseph Cox3,4, Élise Roy2,5, Julie Bruneau6,7.   

Abstract

Recent studies have highlighted the efficacy of and willingness to use pre-exposure prophylaxis (PrEP) to prevent HIV infection among people who inject drugs (PWID), however knowledge of real-world applicability is limited. We aimed to quantify the real-world eligibility for HIV-PrEP among HIV-negative PWID in Montreal, Canada (n = 718). Eligibility was calculated according to US Centers for Disease Control and Prevention (CDC) guidelines and compared to risk of HIV acquisition according to the assessing the risk of contracting HIV (ARCH-IDU) risk screening tool. Over one-third of participants (37%) were eligible for HIV PrEP, with 1/3 of these eligible due to sexual risk alone. Half of participants were considered high risk of HIV acquisition according to ARCH-IDU, but there was poor agreement between the two measures. Although a large proportion of PWID were eligible for HIV-PrEP, better tools that are context- and location-informed are needed to identify PWID at higher risk of HIV acquisition.

Entities:  

Keywords:  HIV prevention; Men who have sex with men; People who inject drugs; PrEP eligibility guidelines; Pre-exposure prophylaxis

Mesh:

Substances:

Year:  2020        PMID: 31997057     DOI: 10.1007/s10461-020-02800-w

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  1 in total

1.  High Rates of Pre-exposure Prophylaxis Eligibility and Associated HIV Incidence in a Population With a Generalized HIV Epidemic in Rakai, Uganda.

Authors:  Victor Ssempijja; Gertrude Nakigozi; Robert Ssekubugu; Joseph Kagaayi; Godfrey Kigozi; Fred Nalugoda; Betty Nantume; James Batte; Grace Kigozi; Ping Teresa Yeh; Hadijja Nakawooya; David Serwadda; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Kate M Grabowski; Larry W Chang; Anja Van't Hoog; Frank Cobelens; Steven J Reynolds
Journal:  J Acquir Immune Defic Syndr       Date:  2022-03-08       Impact factor: 3.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.